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ing the outbreak in French Polynesia during 2013–2014. 
Cases of Guillain-Barré syndrome were also recorded 
during the Zika outbreak in Brazil (6). Moreover, soon 
after health authorities in Brazil warned of an increase in 
the prevalence of microcephaly in newborns that might 
be associated with Zika virus infection in mothers during 
pregnancy, health authorities in French Polynesia con-
firmed that neurologic congenital abnormalities also had 
been observed during the Zika outbreak there (6).
Other lessons learned from the emergence of CHIKV and 
Zika virus in small tropical islands include evidence of non-
vectorborne virus transmission and its associated public health 
implications. Perinatal transmission of Zika virus to a neonate 
was first described in infected pregnant women in French 
Polynesia, and possible transplacental transmission was fur-
ther corroborated by the detection of the virus in amniotic flu-
id samples of 2 pregnant women in Brazil whose fetuses had 
been diagnosed with microcephaly (6). Sexual transmission 
of Zika virus, suggested by Foy et al. (7), was corroborated 
by detection of virus in the semen of a patient in French Poly-
nesia (8). To prevent transmission of CHIKV and Zika virus 
by blood transfusion, local blood banks in French Polynesia 
and the Caribbean adjusted their algorithms for blood dona-
tion and screening of blood products during outbreaks (9,10).
When we observe the geographic distribution of 
DENV, CHIKV, and Zika virus over the past decade, 
DENV expansion appears to have been a continuous pro-
cess. However, the emergence of CHIKV, first in the In-
dian Ocean and later in the Caribbean, and the emergence 
of Zika virus in the Pacific has dramatically expanded the 
reach of these viruses (Figure).
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To the Editor: In sub-Saharan Africa, febrile patients 
are often assumed to have, and are treated for, malaria, but 
when tested, many are malaria-negative. Because emerging 
diseases, such as chikungunya virus (CHIKV) and dengue 
virus (DENV) infections, cause outbreaks around the world 
(1–3), the importance of these pathogens has become more 
evident. However, low-income countries have limited epi-
demiologic data on alternative diagnoses to malaria (4,5) 
and poor laboratory capacity (1), which restrict further 
diagnostic investigations. An early study in Mozambique 
during the 1980s found antibodies to Rift Valley fever virus 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 22, No. 5, May 2016 915
LETTERS
1These authors contributed equally to this article.
(RVFV) in 2% of pregnant women (6). More recently, a 
RVFV seroprevalence of 36.9% among cattle in the Ma-
puto Province was shown in 2010–2011 (7). Furthermore, 
the movement of humans from rural areas to major cities, 
particularly to the capital of Maputo, might affect human 
illnesses and disease pattern of zoonotic viruses (3).
We conducted a pilot study on CHIKV, DENV, hanta-
virus, RVFV, and West Nile virus (WNV) epidemiol-
ogy in Mozambique. Ethical approval (registration no. 
IRB00002657) was granted by the National Bioethics 
Committee in Mozambique and by the Regional Ethical 
Review Board at Karolinska Institutet, Stockholm, Sweden 
(permit no. 2012/974–31/3).
During 2012–2013, a total of 78 febrile patients were 
prospectively enrolled when they sought medical attention 
at the Polana Caniço Health Center and Mavalane Health 
Center (catchment area 4,663 km2, estimated population 
46,184 inhabitants) in the suburban area of Maputo city. 
All included patients answered a questionnaire and were 
initially screened for malaria by blood smear light micros-
copy; 15 were positive for malaria (Table). Patients’ medi-
an age was 29 years (37 years for seropositive patients) and 
ranged from 5 to 78 years. Forty-six (59%) were female. 
Fifty-eight (74%) reported recent exposure to mosquitoes. 
None of these persons had a history of international travel, 
and none had received a yellow fever vaccination.
Sixty (77%) patients provided paired acute- and con-
valescent-phase blood samples, with a minimum of 14 days 
(median 33 days) between samples. Serum samples were 
sent to the Public Health Agency of Sweden and blindly 
screened at a titer of 1:20 for IgG to CHIKV, DENV, hanta-
virus, RVFV, and WNV by using in-house indirect immu-
nofluorescence assays as described for DENV by Vene et 
al. (8). Screening for IgG were done on convalescent-phase 
serum samples or, when those was not available, on acute-
phase serum samples. Further immunofluorescence analy-
ses for titer increases were performed for patients for whom 
paired serum samples were available and screening results 
were positive for IgG; however, no titer increases were 
found. Serum from admittance were tested for DENV IgM 
and WNV IgM by using commercial assays according to 
manufacturers’ instructions (Panbio Dengue IgM Capture 
ELISA E-DEN01M/E-DEN01M05, Standard Diagnostics, 
Inc., Yongin-si, South Korea; Serion ELISA classic ES-
R14M West Nile Virus IgM, Institut Virion/Serion GmbH, 
Würzburg, Germany); 2 samples were positive for DENV 
IgM but none for WNV IgM. All acute serum samples were 
screened by using 1-step real-time reverse transcription 
PCR for CHIKV, RVFV, WNV (in-house validated assays), 
and DENV (9). Results were negative for viral RNA.
Twenty-three (29%) of the 78 patients had a positive 
serology result from acute- or convalescent-phase serum 
samples for >1 of the tested viral pathogens (Table). The 
main finding was CHIKV IgG in 15 (19%) patients. Ten 
(13%) patients had positive results for DENV, including 2 
DENV IgM–positive samples.
The seroepidemiologic findings in this pilot study in 
Maputo strongly suggest possible and neglected alterna-
tive causes of febrile illness in Mozambique. Antibodies 
to CHIKV were found in 19% of the patients, which was 
a novel finding for Mozambique but corresponded well 
with other reports on the spread of CHIKV in tropical and 
subtropical areas of the world (2,3). DENV antibodies 
were present in 13% of the study population, represent-
ing a new finding in southern Mozambique; previous out-
breaks have been reported from the northern part of the 
country (5). The median age of the seropositive patients 
(37 years) was higher than for the group as a whole (29 
years), which might reflect increased exposure to zoo-
notic viruses over time. One patient was IgG positive for 
RVFV, a potentially emerging cause of fever in Mozam-
bique, especially in view of recent reports of RVFV in 
cattle (7). The samples positive for both DENV and WNV 
IgG could represent previous independent infections with 
these viruses, co-infection, or cross-reactivity, which are 
common for flavivirus IgG (10). 
Overall, results indicate that exposure to vectorborne 
viruses in persons living in suburban areas of Maputo city 
is frequent, suggesting that infections with CHIKV, DENV, 
and RVFV infection should be considered as alternative di-
agnoses for patients with febrile illness in these settings. 
On the basis of these results, more extensive research is 
planned on the epidemiology of zoonotic viral infections 
in Mozambique.
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Table. Results of screening for viral antibodies and malaria 
parasites in 78 febrile patients, Maputo, Mozambique,  
2012–2013* 
Organism No. (%) positive† 
Chikungunya virus 15 (19.2) 
Dengue virus 10 (12.8)‡ 
Hantavirus 0 
Rift Valley fever virus 1 (1.3) 
West Nile virus 3 (3.8) 
Malaria parasites 15 (19.2)§ 
*Viral antibody–positive patients had positive IgG or IgM response for >1 
of the zoonotic viruses in acute- or convalescent-phase serum samples. 
The overall malaria screening results for the study cohort is also presented 
†Three of the 23 serology-positive patients were positive for dengue virus 
and West Nile virus IgG, of whom 2 were also positive for chikungunya 
virus IgG and 1 for Rift Valley fever virus IgG. 
‡Including 2 dengue virus IgM-positive samples. 
§Three of 15 malaria-positive patients had a positive serologic finding (2 
for dengue virus IgG and 1 for chikungunya IgG). 
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To the Editor: Relapsing fevers are paroxysmal 
bloodstream infections caused by spirochetes of the genus 
Borrelia. Louseborne relapsing fever (LBRF; i.e., epidemic 
relapsing fever) is caused by B. recurrentis and transmit-
ted by the human body louse (Pediculus humanus). Soft 
ticks of the Argasidae family (e.g., Ornithodorus moubata) 
are vectors for tickborne relapsing fever (TBRF) borreliae, 
which encompass several human-pathogenic species. In 
Europe, LBRF was epidemic in the early 20th century but 
is now rarely seen. We report an infection with B. recur-
rentis imported to Germany by a Somalian refugee who 
had high fever and hemoptysis and describe the process of 
molecular diagnosis.
In August 2015, an 18-year-old man sought asylum in 
Germany after travel through Somalia, Ethiopia, Sudan, Lib-
ya, and Italy. He reported general weakness and fever while 
in Libya, ≈16 days before seeking care, and started cough-
ing up blood after arriving in Italy. At hospital admission in 
Germany, he had a temperature up to 40.4°C, cough, and he-
moptysis; his suspected diagnosis was tuberculosis. No ec-
toparasites were reported or found on physical examination. 
Abnormal laboratory findings included relative neutrophilia 
(91% [reference 39%–77%]), thrombocytopenia (platelets 
112 × 10³/mL [reference 160–385 × 10³/mL]), and prolonged 
activated partial thromboplastin time (APTT) (Figure, panel 
A). Because of highly elevated levels of C-reactive protein 
(250 mg/L [reference <5 mg/L]) and procalcitonin (16.4 
µg/L [reference <0.5 µg/L]), the patient was treated with 
ceftriaxone (2g/d intravenously), metronidazole (500 mg/d 
intravenously), and paracetamol (acetaminophen). Repeated 
examinations of Giemsa-stained thick and thin blood slides 
were negative for malaria parasites. Blood cultures, tests for 
tuberculosis, and PCRs for Rift Valley fever, yellow fever, 
dengue, and chikungunya viruses also were negative. With 
antimicrobial therapy, the patient’s fever declined within 12 
hours, but platelet counts further decreased and APTT con-
tinued to increase (Figure, panel A).
The patient’s symptoms and travel history raised sus-
picion of a spirochete infection. A plasma sample from his 
second day in the hospital tested positive for Borrelia spp. 
16S DNA by real-time PCR (1). Retrospective microscopy 
revealed a low number of extracellular spirochetes in thin 
blood smears (Figure, panel B). The antimicrobial regimen 
was changed to doxycycline (100 mg 2×/d) on day 7 after 
admission and, because species identification had not been 
completed, continued for 10 days. No signs of a Jarisch-
Herxheimer reaction were seen. During days 4–9 after ad-
mission, APTT, platelet counts (Figure, panel A), and C-
reactive protein values returned to normal, and the patient 
was discharged.
For species identification, we amplified the entire cod-
ing sequence of glpQ (glycerophosphodiester phosphodi-
esterase) with newly designed primers (online Technical 
Appendix, http://wwwnc.cdc.gov/EID/article/22/5/15-1557-
Techapp1.pdf). The amplicon was 100% (1,002/1,002 bp) 
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